| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Tracheal smooth muscle receptors; inflammatory mediators; neuroactive targets. Yubeinine acts as a tracheal relaxant, relaxing smooth muscle in the airways. The mechanism likely involves modulation of calcium channels, β-adrenergic receptors, or other signaling pathways that regulate smooth muscle contraction. The compound also exhibits anti-inflammatory activity by inhibiting the secretion of inflammatory cytokines and chemokines. It protects against oxidative stress in mice with hepatitis. Yubeinine's neuroactive potential suggests interactions with neurotransmitter systems or neuroprotective pathways. The compound's diverse bioactivities highlight potential therapeutic applications in respiratory disorders, inflammation, and neuroprotection research.
|
|---|---|
| ln Vitro |
Yubeinine is an alkaloid with tracheal relaxant effects. In vitro studies have shown that yubeinine inhibits the secretion of inflammatory cytokines and chemokines. The compound has anti-inflammatory properties and protects against oxidative stress. Beyond its respiratory benefits, Yubeinine has demonstrated anti-inflammatory and neuroactive potential. Its hepatoprotective effects have been observed, with inhibition of inflammatory mediators responsible for liver damage. The compound's diverse bioactivities suggest potential therapeutic applications in respiratory disorders, inflammation, and neuroprotection.
|
| ln Vivo |
In vivo studies of yubeinine have demonstrated its hepatoprotective effects in mice with hepatitis. The compound protects against oxidative stress and inhibits the secretion of inflammatory cytokines and chemokines responsible for liver damage. Its tracheal relaxant effects suggest potential applications in respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The compound's anti-inflammatory and neuroactive potential support further investigation in neurological and immunological studies.
|
| Enzyme Assay |
Non-cell-based assays for yubeinine include enzyme inhibition studies and receptor binding assays. Tracheal relaxant activity can be assessed using isolated tracheal rings in organ baths, measuring relaxation responses to various concentrations of the compound. Anti-inflammatory activity can be assessed by measuring inhibition of inflammatory mediators in enzyme assays. Antioxidant activity can be assessed using DPPH, ABTS, or FRAP assays. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for yubeinine use various cell lines to assess its biological activities. For tracheal relaxant studies, airway smooth muscle cells can be used to study effects on calcium signaling and contraction. For anti-inflammatory studies, macrophage cell lines (e.g., RAW 264.7) are stimulated with LPS and treated with the compound, and inflammatory mediators (cytokines, chemokines) in culture supernatant are measured. For hepatoprotective studies, hepatocytes or hepatic cell lines are treated with hepatotoxic agents with or without the compound, and cell viability and enzyme levels are measured. Neuroactive effects can be assessed in neuronal cell lines.
|
| Animal Protocol |
In vivo studies of yubeinine have been conducted in mouse models of hepatitis. The compound protects against oxidative stress and inhibits the secretion of inflammatory cytokines and chemokines responsible for liver damage. Potential animal models for further studies include: ovalbumin-induced asthma models for tracheal relaxant evaluation; and LPS-induced sepsis models for anti-inflammatory evaluation. Standard protocols for these models involve administration of the compound (oral, intraperitoneal, or intravenous) followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Yubeinine has a molecular formula of C₂₇H₄₃NO₃ and a molecular weight of 429.64 g/mol. It is an alkaloid natural product. The compound is soluble in organic solvents such as DMSO. It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for 1 year. It is intended for research use only and is not for human consumption. Specific solubility and formulation information may vary and should be determined experimentally.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for yubeinine are limited. As a natural alkaloid, it may have biological activity at certain concentrations. The compound exhibits anti-inflammatory and hepatoprotective effects, suggesting potential therapeutic benefits rather than toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
Kashmirine has reportedly been found in Fritillaria ebeiensis, Fritillaria thunbergii var. chekiangensis, and other organisms with available data. See also: Imperial pigment (note moved to).
Yubeinine is an alkaloid natural product with diverse biological activities including tracheal relaxant, anti-inflammatory, hepatoprotective, and neuroactive effects. The compound's tracheal relaxant properties make it of interest for respiratory disorder research, including asthma and COPD. Its anti-inflammatory and hepatoprotective effects suggest potential applications in liver disease and inflammatory conditions. The compound's neuroactive potential supports investigation in neurological studies. Yubeinine is a natural product that may contribute to the pharmacological effects of its source plant. It is for research use only. |
| Molecular Formula |
C27H43NO3
|
|---|---|
| Molecular Weight |
429.63500
|
| Exact Mass |
429.324
|
| CAS # |
157478-01-8
|
| PubChem CID |
5221
|
| Appearance |
White to off-white solid
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
31
|
| Complexity |
755
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IQDIERHFZVCNRZ-UUSLGJCMSA-N
|
| InChi Code |
InChI=1S/C27H43NO3/c1-15-4-7-25-27(3,31)21-6-5-17-18(20(21)14-28(25)13-15)11-22-19(17)12-24(30)23-10-16(29)8-9-26(22,23)2/h15-23,25,29,31H,4-14H2,1-3H3/t15?,16-,17?,18?,19?,20?,21?,22?,23?,25?,26-,27+/m1/s1
|
| Chemical Name |
(10S,20R,23R)-10,20-dihydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosan-17-one
|
| Synonyms |
Yubeinine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (232.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3275 mL | 11.6377 mL | 23.2753 mL | |
| 5 mM | 0.4655 mL | 2.3275 mL | 4.6551 mL | |
| 10 mM | 0.2328 mL | 1.1638 mL | 2.3275 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
